

**From:** [REDACTED]@AstraZeneca.com>  
**Sent:** mardi 19 janvier 2021 16:47  
**To:** GALLINA Sandra (SANTE); SANTE CONSULT-C3; SANTE CONSULT-A3;  
EC VACCINES; [REDACTED] (SANTE)  
**Cc:** [REDACTED]  
**Subject:** SARS CoV-2 Vaccine [REDACTED] 19 January 2021  
**Attachments:** SARS CoV-2 [REDACTED] 19Jan2021 for  
EC.pdf; UKPAR\_COVID\_19\_Vaccine\_AstraZeneca\_05.01.2021.pdf;  
Summary of the Public Assessment Report for AstraZeneca COVID-  
19 vaccine - GOV.UK.pdf

**Categories:** Goals/Objectives

Dear Ms Gallina,

In response to the letter you submitted on 14 December 2020, please find enclosed the following documents to address [REDACTED] regarding AZ [REDACTED] development of the COVID-19 vaccine:

1. The AZ generated SARS CoV-2 Vaccine [REDACTED]
2. The Public Assessment Report issued by the MHRA
3. The Summary of the Public Assessment Report issued by the UK Government

Should you have any questions please do let me know.

Thank you for your patience and look forward to speaking with you later this week.

Best regards,

[REDACTED]

[REDACTED]

[REDACTED]

AstraZeneca | [REDACTED]

E: [REDACTED]@astrazeneca.com

---

**Confidentiality Notice:** This message is private and may contain confidential and proprietary information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this message is not permitted and may be unlawful.